Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
IXICO plc ( (GB:IXI) ) has provided an update.
IXICO plc reported strong financial results for the year ending September 2025, with a 13% increase in revenue and a 21% reduction in EBITDA loss, driven by its Innovate Lead Scale strategy. The company achieved significant growth in its order book and expanded its operations in North America, while also diversifying revenue streams and enhancing its AI-powered platform. These advancements position IXICO to continue its leadership in neuroimaging and biomarker analytics, benefiting stakeholders by accelerating drug development for neurological disorders.
The most recent analyst rating on (GB:IXI) stock is a Hold with a £12.00 price target. To see the full list of analyst forecasts on IXICO plc stock, see the GB:IXI Stock Forecast page.
Spark’s Take on GB:IXI Stock
According to Spark, TipRanks’ AI Analyst, GB:IXI is a Neutral.
IXICO plc’s overall stock score reflects significant financial challenges, particularly in revenue generation and profitability, which are the most impactful factors. Technical indicators suggest a lack of strong momentum, and valuation metrics highlight profitability issues. The absence of earnings call data and corporate events limits additional insights.
To see Spark’s full report on GB:IXI stock, click here.
More about IXICO plc
IXICO plc is a global leader in neuroscience imaging and biomarker analytics, utilizing its AI-driven platform to advance the treatment of neurological disorders. The company operates as an Imaging Contract Research Organisation (iCRO), supporting clinical trials and working with pharmaceutical companies, biotech firms, and non-profit organizations. IXICO focuses on diseases such as Alzheimer’s, Huntington’s, and Parkinson’s, providing precise measurement of imaging biomarkers to aid in drug discovery and development.
Average Trading Volume: 89,717
Technical Sentiment Signal: Sell
Current Market Cap: £9.96M
Learn more about IXI stock on TipRanks’ Stock Analysis page.